Microbix Biosystems Inc.

265 articles with Microbix Biosystems Inc.

• Microbix Presenting Test Validation Methods at AACCUsage of QAPs to Validate Whole Workflow Quality Control of Testing

  6/3/2022

  Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, announces it is presenting about the utility of its Quality Assessment Products (“ QAPs™ ”) to monitor the end-to-end diagnostic process, including the impact of “preanalytical” sample-handling variables on test accuracy, at the 2022 “Preanalytical Phase Conference” of the American Association of Clinical Chemistry.

• Microbix Reports Record Results for Q2 Fiscal 2022Record Q2 Sales of $4.9 million, Q2 Net Earnings of $0.7 million

  5/12/2022

  Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix ® ), a life sciences innovator, manufacturer, and exporter, reports results for its second quarter and first half of fiscal 2022 ended March 31, 2022,

• Microbix Presenting Omicron Test Control Results at CVSQAPs Supporting Molecular Diagnostic Tests for Dominant COVID-variant

  4/29/2022

  Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), announces it will present performance results of its Quality Assessment Products (“QAPs™”) supporting molecular-diagnostic tests for the Omicron variant of the SARS-CoV-2 virus (“Omicron”) at the 2022 Clinical Virology Symposium of the American Society for Microbiology (“CVS”) taking place in West Palm Beach, Florida from May 1-4, 2022.

• Microbix Presenting at the 2022 Bloom Burton ConferenceHealthcare Investor Conference in Toronto on May 2 & 3, 2022

  4/28/2022

  Microbix Biosystems Inc. announces it will be attending and presenting at the Bloom Burton & Co. Healthcare Investor Conference taking place at the Metro Toronto Convention Centre, North Building, in Toronto, Ontario, Canada on May 2nd and 3rd, 2022.

• Microbix Presenting Respiratory Virus Controls Data at Two Events

  4/19/2022

  Microbix Biosystems Inc. announces it will be presenting performance results of its quality assessment products that support molecular-diagnostic screening-tests for respiratory viruses at two industry congresses – “Labquality Days” in Helsinki, Finland April 20-21, 2022 and “ECCMID 2022” in Lisbon, Portugal, April 23-26, 2022.

• Microbix Presenting HPV Product Results at EUROGINQAPs Supporting Screening-Tests for High-Risk Human Papilloma Viruses

  4/8/2022

  Microbix Biosystems Inc. announces it will present performance results of its Quality Assessment Products (“ QAPs™ ”) supporting Human Papillomavirus (“ HPV ”) molecular-diagnostic screening-tests at the 2022 annual congress of the European Research Organization on Genital Infection and Neoplasia (“ EUROGIN ”) taking place in Düsseldorf, Germany from April 10=12, 2022.

• Microbix Invests to Further Scale Its Business

  3/29/2022

  Microbix Biosystems Inc., a life sciences innovator and exporter, announces investment in programs to upgrade, digitize and fully-integrate its Quality Management System and its Enterprise Resource Planning platforms — to better enable its business growth trajectory.

• Microbix Announces Issuance of Stock Options - Feb 24, 2022

  2/24/2022

  Microbix Biosystems Inc. announces the issuance of stock options under its shareholder-approved 2018 stock option plan, as part of its compensation programs to incentivize and retain its board of directors, executives, and managers.

• Microbix Announces Nomination to Board of DirectorsFor Appointment of Jennifer Stewart, Accomplished Business Leader

  2/22/2022

  Microbix Biosystems Inc. announces that Ms. Jennifer Stewart, an accomplished leader in Canadian business, government, and public affairs, has been nominated to become a member of its Board of Directors.

• Microbix Presenting at Capital Conference in B.C.Meetings with Growth-Oriented Investors, February 18-20, 2022

  2/17/2022

  Microbix Biosystems Inc., a life sciences innovator and exporter, announces that it will be presenting to equity investors at the Whistler Capital Conference, organized by Capital Event Management Ltd. and being hosted at the Fairmont Chateau Whistler, in Whistler, B.C., February 18-20, 2022.

• Microbix Advances Commissioning of Sites Two and Three

  2/15/2022

  Microbix Biosystems Inc., a life sciences innovator and exporter, announces progress with expanding manufacturing capacity of its portfolio of Quality Assessment Products and its “DxTM™” brand viral transport medium – via renovating and equipping its second and third manufacturing sites in Mississauga, ON.

• Microbix Reports Record Results for Q1 Fiscal 2022Record Q1 Sales of $4.9 million, Record Q1 Net Earnings of $0.9 million

  2/10/2022

  Microbix Biosystems Inc. reports results for its first quarter ended December 31, 2021.

• Microbix Launches Omicron Variant Test Control

  2/1/2022

  Microbix Biosystems Inc. announces the expansion of its portfolio of Quality Assessment Products to include a swab-formatted control that helps validate the accuracy and integrity of the workflows of nucleic-acid based tests for SARS-CoV-2 Wuhan strain and the Omicron variant – the latter now being the most prevalent form of COVID.

• Microbix Receives $4.7 Million Order for Viral Transport MediumFollow-on Order from Government of Ontario Procurement Authorities

  12/24/2021

  Microbix Biosystems Inc. announces receipt of a follow-on order of C$ 4.7 million for its viral transport medium (generically known as “ VTM ” and branded “ DxTM™ ” by Microbix). DxTM is a sample-collection device that is essential for PCR-based testing for viruses that cause COVID-19 disease.

• Microbix Reports Record Results for Fiscal 2021Record Sales of $18.6 million, Record Net Earnings of $3.2 million

  12/23/2021

  Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix ® ), a life sciences innovator and exporter, reports results for its year and fourth quarter ended September 30, 2021 (“ 2021 ” and “ Q4 ”), with record sales and earnings, plus progress upon its strategic goal of increasing the proportion of revenues derived from medical devices.

• Microbix Expands Pandemic Test Controls (QAPs™) PortfolioHelping Ensure Workflow Accuracy of PCR Tests for COVID “Variants of Concern”

  11/17/2021

  Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator and exporter, announces the expansion of its portfolio of Quality Assessment Products (“QAPs™”) to include controls that support PCR tests for each of the four major variants of concern (“VOCs”) of the SARS-CoV-2 virus that is the cause of the COVID-19 pandemic.

• Microbix Receives $2.7 Million from Exercise of Warrants

  10/27/2021

  Microbix Biosystems Inc., a life sciences innovator and exporter, announces that it has received C$ 2.7 million from the partial exercise of two series of expiring share purchase warrants.

• Microbix Makes Early Repayment of 9% Interest Debenture

  10/4/2021

  Microbix Biosystems Inc., a life sciences innovator and exporter, announces that it has completed the early repayment of a debenture series on which it owed C$ 1.3 million and was paying an interest rate of 9.0%.

• Microbix Presenting Product Results at AACCQAPs to Support Testing for COVID Viral Variants

  9/27/2021

  Microbix Biosystems Inc., a life sciences innovator and exporter, announces that it has been invited to present about the performance of its COVID-19 test quality assessment products at “AACC” the annual scientific meeting & clinical laboratory exposition of the American Association of Clinical Chemistry, taking place in live and virtual formats from Atlanta, GA, September 26-30, 2021.

• Microbix Presenting at Muskoka Capital Conference Meetings with Growth-Oriented Investors, September 24-26, 2021

  9/23/2021

  Microbix Biosystems Inc., a life sciences innovator and exporter, announces that it will be presenting to investors at the Muskoka Capital Conference, organized by Capital Event Management Ltd. and being hosted at the JW Marriott Rosseau Muskoka, in Minett, ON, September 24-26, 2021.